Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORE LABORATORIES N VCLB · Entity 11862 | CAO & Treasurer | February 16, 2023 | February 21, 2023 |
| Core Laboratories Inc. /DE/CLB · Entity 5382 | CAO & Treasurer | February 15, 2024 | February 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORE LABORATORIES N V
Report date February 16, 2023 · Filed February 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 12,240 |
Reported balance
After 2023-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-16 · Grant · Acquired 12,240 · Balance 12,240 F1: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). At the end of the Performance Period, 50% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 100% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 50% up to 100% of the award). |
Filing footnotes · ownership attribution and instrument terms
F1: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). At the end of the Performance Period, 50% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 100% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 50% up to 100% of the award).
Core Laboratories Inc. /DE/
Report date February 15, 2024 · Filed February 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,882 |
Reported balance
After 2024-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-15 · Grant · Acquired 8,882 · Balance 8,882 F1: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the"Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 200% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 100% up to 200% of the award). |
Filing footnotes · ownership attribution and instrument terms
F1: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the"Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 200% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 100% up to 200% of the award).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2019 Filed Dec 3, 2019 15:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058662 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 15:58 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 105 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000065 · wf-form4_156218386529407.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,340 Underlying: Common Shares · 105 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.exercise_date: Multiple restricted share grants are included in this total. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: Multiple restricted share grants are included in this total. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 15:58 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 41 | $52.88 | $2,168.08 |
DisclosureSEC source: 0001000229-19-000065 · wf-form4_156218386529407.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454 Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 15:58 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 105 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000065 · wf-form4_156218386529407.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:11 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 70 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000049 · wf-form4_155423588696870.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,445 Underlying: Common Shares · 70 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.exercise_date: Multiple restricted share grants are included in this total. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: Multiple restricted share grants are included in this total. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:11 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 32 | $68.93 | $2,205.76 |
DisclosureSEC source: 0001000229-19-000049 · wf-form4_155423588696870.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390 Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 16:11 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 70 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000049 · wf-form4_155423588696870.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 16:11 UTC | CORE LABORATORIES N V CLB · Entity 11862 | SaleCommon Shares | 428 | $66.25 | $28,355.00 |
DisclosureSEC source: 0001000229-19-000035 · wf-form4_155242145406970.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:20 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 120 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000030 · wf-form4_155182079028278.xml · derivative · entry 6 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,515 Underlying: Common Shares · 120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.exercise_date: Multiple restricted share grants are included in this total. The 1,515 shares are the total remaining unvested RSAPs for this reporting person. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: Multiple restricted share grants are included in this total. The 1,515 shares are the total remaining unvested RSAPs for this reporting person. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:20 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 110 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000030 · wf-form4_155182079028278.xml · derivative · entry 5 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,635 Underlying: Common Shares · 110 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:20 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingRestricted Shares | 54 | $67.37 | $3,637.98 |
DisclosureSEC source: 0001000229-19-000030 · wf-form4_155182079028278.xml · nonDerivative · entry 4 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:20 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000030 · wf-form4_155182079028278.xml · nonDerivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:20 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingRestricted Shares | 50 | $67.37 | $3,368.50 |
DisclosureSEC source: 0001000229-19-000030 · wf-form4_155182079028278.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:20 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares | 110 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000030 · wf-form4_155182079028278.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 16:24 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 3,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-19-000025 · wf-form4_155017948418004.xml · derivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Underlying: Common Shares · 3,800 shares Expires not disclosed F1 · derivative.exercise_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, this award would vest at the end of a three-year performance period that began on January 1, 2019 and ends on December 31, 2021 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If this criteria is not met, then no shares shall vest and the award shall be forfeited. F1 · derivative.expiration_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, this award would vest at the end of a three-year performance period that began on January 1, 2019 and ends on December 31, 2021 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If this criteria is not met, then no shares shall vest and the award shall be forfeited. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:30 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000123 · wf-form4_154395901449324.xml · derivative · entry 6 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,745 Underlying: Common Shares · 800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This completes the vesting of a special grant that was awarded on 12/1/14 and vested on December 1 of 2016, 2017 and 2018. F2 · derivative.expiration_date: This completes the vesting of a special grant that was awarded on 12/1/14 and vested on December 1 of 2016, 2017 and 2018. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:30 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 140 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000123 · wf-form4_154395901449324.xml · derivative · entry 5 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,545 Underlying: Common Shares · 140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:30 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingRestricted Shares | 308 | $83.11 | $25,597.88 |
DisclosureSEC source: 0001000229-18-000123 · wf-form4_154395901449324.xml · nonDerivative · entry 4 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654 Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:30 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000123 · wf-form4_154395901449324.xml · nonDerivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:30 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingRestricted Shares | 54 | $83.11 | $4,487.94 |
DisclosureSEC source: 0001000229-18-000123 · wf-form4_154395901449324.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162 Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:30 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000123 · wf-form4_154395901449324.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2018 Filed Sep 5, 2018 17:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000108 · wf-form4_153618238091216.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,685 Underlying: Common Shares · 125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Multiple restricted share grants are included in this total. F2 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: Multiple restricted share grants are included in this total. F2 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document |
| September 01, 2018 Filed Sep 5, 2018 17:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingRestricted Shares | 49 | $114.55 | $5,612.95 |
DisclosureSEC source: 0001000229-18-000108 · wf-form4_153618238091216.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76 Read SEC document |
| September 01, 2018 Filed Sep 5, 2018 17:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares | 125 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000108 · wf-form4_153618238091216.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:22 UTC | CORE LABORATORIES N V CLB · Entity 11862 | SaleRestricted Shares | 73 | $112.63 | $8,221.99 |
DisclosureSEC source: 0001000229-18-000102 · wf-form4_153436453203250.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 16:39 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 105 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000090 · wf-form4_153065036805977.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,810 Underlying: Common Shares · 105 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Multiple restricted share grants are included in this total. F2 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: Multiple restricted share grants are included in this total. F2 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 16:39 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingRestricted Shares | 32 | $126.21 | $4,038.72 |
DisclosureSEC source: 0001000229-18-000090 · wf-form4_153065036805977.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73 Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 16:39 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares | 105 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000090 · wf-form4_153065036805977.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.